Retacrit®, Biosimilar of Epoetin Alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation
Sign Up to like & getrecommendations! Published in 2022 at "Oncology"
DOI: 10.1159/000522069
Abstract: Introduction: The aim of the study was to evaluate in real-life conditions the effectiveness and safety of a biosimilar of epoetin alfa (Retacrit®) in chemotherapy-induced anemia and the impact of iron supplementation. Methods: This was… read more here.
Keywords: iron supplementation; supplementation; chemotherapy induced; epoetin alfa ... See more keywords
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2020111638
Abstract: BACKGROUND Concerns regarding cardiovascular safety with current treatments for anemia in patients with dialysis-dependent (DD)-CKD have encouraged the development of alternatives. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoietin… read more here.
Keywords: epoetin alfa; dialysis; roxadustat; anemia patients ... See more keywords